Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial

No­vo Nordisk’s late-stage weight loss da­ta showed Ca­griSe­ma per­formed be­low an­a­lysts’ ex­pec­ta­tions.

It’s the sec­ond late-stage clin­i­cal let­down for the can­di­date, and the find­ings mean …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.